Zuckerman出售了图标 Plc的股份,而Prosight购买了更多的股票,因为机构所有权仍然很高。 Zuckerman sold shares in Icon Plc, while Prosight bought more, as institutional ownership remains high.

扎克曼投资集团在2025年第三季度将其在Icon Plc的股权减少了4.1%,出售了6,456股,而Prosight Management LP则将其持股量增加了11.1%,达到109,500股,使其成为该公司第八大持股. Zuckerman Investment Group reduced its stake in Icon Plc by 4.1% in Q3 2025, selling 6,456 shares, while Prosight Management LP increased its position by 11.1% to 109,500 shares, making it the company’s eighth-largest holding. 作为全球药物开发和临床研究服务提供商的Icon的市值为794亿美元,交易价为98.33美元,分析师的评级平均为"持有",目标价为146.80美元. Icon, a global drug development and clinical research services provider, has a market cap of $7.94 billion and trades at $98.33, with a mixed analyst rating averaging "Hold" and a target price of $146.80. 机构投资者拥有公司95.6%的股份。 Institutional investors own 95.6% of the company’s shares.